Please login to the form below

Not currently logged in
Email:
Password:

Novo Nordisk's US subsidiary hires new president

Novo Nordisk, the Danish-headquartered diabetes company, hires Jerzy Gruhn as president of Novo Nordisk Inc, the company's US subsidiary

Novo Nordisk, the Danish-headquartered diabetes company, has appointed Jerzy Gruhn as president of Novo Nordisk Inc, the company's US subsidiary.

Gruhn will also serve as senior vice-president of Novo Nordisk North America.

Gruhn will replace Martin Soeters, who will take up the position of senior vice-president European region. Soeters will oversee the company's operations in 35 countries. Gruhn is currently vice-president of the Eastern Europe region. The appointments will take effect at the beginning of 2008.

Gruhn, who has worked for the company for 10 years, has played a critical role in the company's growth. In his current position as vice-president of the Europe East region, he overcame strong competitive pressures and adverse market conditions caused by pricing reforms and reimbursement issues to expand the company's business in the region to 16 countries with diverse cultures and market dynamics.

Soeters has more than 27 years' experience in Novo Nordisk in executive management, sales and marketing. Since he took over responsibility for the company's operations in the North American region in 2000, he grew annual sales from USD 500m in FY00 to USD 2.1bn in FY06.

4th September 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

Beyond the event
...
Anthill Agency and Actando partnership to Transform Pharma's Digital Skills
Anthill Agency, a leading life sciences digital agency, today announced the launch of the Anthill Academy™ and partnership with Actando's PharmAcademy....
Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...

Infographics